MDAI Stock Risk & Deep Value Analysis
Spectral AI Inc
Healthcare • Medical Devices
DVR Score
out of 10
What You Need to Know About MDAI Stock
We analyzed Spectral AI Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran MDAI through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
MDAI Risk Analysis & Red Flags
What Could Go Wrong
Despite improved cash, the company still has negative equity and relies heavily on BARDA funding. If commercial sales do not materialize quickly post-De Novo approval, or if the BARDA contract faces significant delays, the company could face another severe liquidity crisis requiring highly dilutive financing, severely impacting shareholder value.
Risk Matrix
Overall
Aggressive
Financial
High
Market
Medium
Competitive
Medium
Execution
High
Regulatory
Medium
Red Flags
- ⚠
Negative shareholder equity (-$5.7 million as of Dec 31, 2025)
- ⚠
Declining FY25 revenue (down from $29.6M to $19.7M)
- ⚠
Continued reliance on grant-based R&D revenue (BARDA) with limited commercial sales traction
- ⚠
Analyst price target reduction from $3 to $2 by BTIG
Upcoming Risk Events
- 📅
Delays or denial of De Novo 510(k) approval
- 📅
Slower-than-expected commercialization or adoption rates
- 📅
Significant delays or changes to the BARDA contract
When to Reconsider
- 🚪
Failure to secure De Novo 510(k) approval within the next 12 months
- 🚪
Cash balance drops below $10 million without clear funding path or significant commercial sales ramp-up
- 🚪
Announcements of highly dilutive financing rounds (e.g., >20% dilution in a single event)
Unlock MDAI Risk Analysis & Red Flags
Create a free account to see the full analysis
What Does Spectral AI Inc (MDAI) Do?
Market Cap
$60.15M
Sector
Healthcare
Industry
Medical Devices
Employees
78
Spectral AI, Inc., an artificial intelligence (AI) company, focuses on predictive medical diagnostics in the United States. The company offers DeepView System, which uses proprietary AI algorithms to distinguish between fully damaged, partially damaged, and healthy human tissue characteristics invisible to the naked eye at the initial time point of wound presentation; and delivers a binary prediction on the wounds capacity to heal or not heal by a specified time point in the future to assist the physician in making a more accurate, timely, and informed decision regarding the treatment of the patient's wounds. Its system also includes MSI imaging technology, which consists of proprietary multi-spectral optics and sensors that capture injured tissue images; and AI-Burn software. Spectral AI, Inc. is headquartered in Dallas, Texas.
Visit Spectral AI Inc WebsiteInvestment Thesis
Spectral AI is a high-risk, high-reward investment leveraging its FDA-cleared and BARDA-validated AI-driven DeepView platform to potentially revolutionize wound diagnostics, particularly for burns. Recent BARDA funding and De Novo submission significantly de-risk its financial position and expand its market opportunity. Success hinges on a swift transition from R&D to robust commercialization, positioning it for potential market leadership in its specialized niche and substantial 10x growth.
Is MDAI Stock Undervalued?
Unlock the full AI analysis for MDAI
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
MDAI Price Targets & Strategy
12-Month Target
$2.75
Bull Case
$5.00
Bear Case
$1.00
Valuation Basis
Assumes a conservative 3.5x P/S multiple on a projected FY27 revenue run-rate of $25M (BARDA + early commercial sales), yielding a market capitalization of $87.5M, or $2.72 per share on approximately 32.16 million shares outstanding.
Entry Strategy
Dollar-cost average between $1.70 - $2.00, targeting support levels around current price and recent lows to manage volatility.
Exit Strategy
Take 50% profit at $3.50; consider full exit or re-evaluate thesis if commercial traction fails to materialize by Q4 2027. Stop loss at $1.20.
Portfolio Allocation
5% for aggressive risk tolerance, given the early stage and significant growth potential balanced by high financial and execution risks.
Price Targets & Strategy
Upgrade to Premium for price targets and entry/exit strategies
Is MDAI Financially Healthy?
Valuation
P/E Ratio
-7.90
Price/Sales
3.10
Profitability
Gross Margin
45.42%
Operating Margin
-43.78%
Net Margin
-38.53%
Return on Equity
-730.01%
Revenue Growth
-33.57%
EPS
$-0.29
Balance Sheet
Current Ratio
0.94
Quick Ratio
0.86
Total Debt
$8.39M
Cash & Equivalents
$15.40M
Other
Beta (Volatility)
1.06
Does MDAI Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Expanding
Moat Sources
2 Identified
The moat's durability hinges on continued regulatory approvals, robust intellectual property protection, and successful integration of the DeepView system into clinical practice, fostering significant switching costs for healthcare providers. The substantial BARDA contract provides a strong, near-term competitive buffer.
Moat Erosion Risks
- •Rapid advancements or new entrants from competitors with superior AI solutions
- •Failure to achieve widespread clinical adoption despite regulatory approvals
- •Challenges in protecting intellectual property globally
MDAI Competitive Moat Analysis
Sign up to see competitive advantages
MDAI Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Neutral. Limited widespread retail discussion, but positive sentiment among niche healthcare/AI investment communities due to BARDA/FDA news.
Institutional Sentiment
Mixed. Vanguard increased holdings by 37.3% (Q4 2025), indicating institutional interest. However, BTIG lowering its price target suggests caution.
Insider Activity (Form 4)
No Form 4 filings reporting insider buying or selling activity in the last 90 days (Jan 18 - Apr 18, 2026).
Options Flow
Normal options activity; no specific unusual put/call ratio or large block trades indicative of strong institutional directional bets reported.
Earnings Intelligence
Next Earnings
Estimated late May / early June 2026 for Q1 2026 results.
Surprise Probability
Medium. Revenue is largely tied to BARDA contract milestones, making it somewhat predictable, but initial commercial sales (if any) could provide unexpected upside or downside.
Historical Earnings Pattern
Volatile stock price reaction based on significant news, as is typical for early-stage biotechnology or medtech companies heavily reliant on regulatory approvals and funding.
Key Metrics to Watch
Competitive Position
Top Competitor
No specific direct AI-driven burn diagnostics competitor identified in the research. Closest would be broader wound care device companies or AI medical imaging firms, but none with the specific DeepView niche and regulatory/BARDA validation.
Market Share Trend
Currently negligible in commercial markets, but has the potential to gain significant market share in the emerging niche of AI-driven burn diagnostics due to its first-mover advantage and regulatory clearances.
Valuation vs Peers
Difficult to compare directly without specific peers identified. Current TTM P/S of 3.04x ($60.31M MC / $19.7M revenue) is not excessively high for a high-growth med-tech company, but the revenue is almost entirely R&D, not commercial sales.
Competitive Advantages
- •FDA-cleared DeepView System for wound assessment
- •Significant BARDA contract funding and validation
- •Proprietary AI algorithms and intellectual property
- •First-mover advantage in specialized AI burn diagnostics
Market Intelligence
Get sentiment, earnings intel, and peer analysis with Premium
What Could Drive MDAI Stock Higher?
Near-Term (0-6 months)
- •De Novo 510(k) approval for DeepView burn diagnostics (submitted March 24, 2026)
- •Q1 2026 earnings report (estimated late May / early June 2026)
- •Further BARDA contract milestones and funding releases
Medium-Term (6-18 months)
- •Initial commercial sales and adoption of DeepView System beyond R&D revenue
- •Strategic partnerships for distribution or technology integration
- •Expansion of DeepView application to other wound types
Long-Term (18+ months)
- •DeepView becoming the standard of care for burn and wound assessment
- •Development of new AI applications in diagnostic imaging
- •Global market expansion for DeepView technology
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for MDAI?
- ✓
Acceleration in commercial revenue growth for DeepView System
- ✓
Positive updates or full approval of the De Novo 510(k) submission
- ✓
Attainment of cash flow positivity and reduced reliance on external funding
Bull Case Analysis
See what could go right with Premium
Competing with MDAI
See how Spectral AI Inc compares to related companies
| Company | Market Cap | DVR Score | P/E | Revenue | Profit Margin | Rev Growth | |
|---|---|---|---|---|---|---|---|
Spectral AI Inc MDAI | $60.1M | 6.8 | -7.9 | $19.6M | -38.5% | -33.6% | |
AbbVie Inc ABBV | $403.8B | 0.1 | 171.8 | — | — | — | Compare → |
Johnson & Johnson JNJ | — | 1.0 | — | — | — | — | Compare → |
Eli Lilly and Co LLY | $965.0B | 0.5 | 52.6 | — | — | — | Compare → |
Pfizer Inc PFE | $150.6B | 0.2 | 19.4 | $62.6B | 12.4% | -1.6% | Compare → |
UnitedHealth Group Inc UNH | $276.2B | 0.3 | 22.9 | $113.7B | 2.7% | 1181.0% | Compare → |
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
How Spectral AI Inc Makes Money
Spectral AI develops and intends to commercialize the DeepView System, an advanced AI-powered diagnostic device designed to accurately assess wound healing and severity, with an initial focus on burn injuries. Currently, the company primarily generates revenue through substantial government R&D contracts, most notably from the Biomedical Advanced Research and Development Authority (BARDA), which funds the ongoing development, validation, and advanced procurement of its technology. In the future, Spectral AI aims to shift towards generating revenue through direct sales and potentially licensing agreements for its DeepView system to hospitals, burn centers, and clinics, transitioning from a grant-funded R&D model to a commercial hardware-plus-AI-software-as-a-service model.
Read Full Business Model BreakdownFAQ
What is the DVR Score for Spectral AI Inc (MDAI)?
As of April 18, 2026, Spectral AI Inc has a DVR Score of 6.8 out of 10, placing it in the "Solid Pick" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Spectral AI Inc?
Spectral AI Inc's market capitalization is approximately $60.1M. The company operates in the Healthcare sector within the Medical Devices industry.
What ticker symbol does Spectral AI Inc use?
MDAI is the ticker symbol for Spectral AI Inc. The company trades on the NCM.
What is the risk level for MDAI stock?
Our analysis rates Spectral AI Inc's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
What is the P/E ratio of MDAI?
Spectral AI Inc currently has a price-to-earnings (P/E) ratio of -7.9. This is below the market average, which could indicate the stock is undervalued or facing headwinds.
Is Spectral AI Inc's revenue growing?
Spectral AI Inc has reported revenue growth of -33.6%. Revenue has been declining, which warrants closer examination.
Is MDAI stock profitable?
Spectral AI Inc has a profit margin of -38.5%. The company is currently unprofitable.
How often is the MDAI DVR analysis updated?
Our AI-powered analysis of Spectral AI Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on April 18, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for MDAI (Spectral AI Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.